Ratings by Jefferies (Dennis Ding)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2026 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2026 | SpyGlass Pharma | SGP | New Coverage | Buy (N/A) |
26.73 (26.68) |
-0.19% | Details | |
| 1/22/2026 | Amicus Therapeutics | FOLD | Downgrade | Hold (Buy) |
14.31 (14.34) |
0.21% | Details | |
| 12/29/2025 | Inhibikase Therapeutics Inc | IKT | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2025 | Assembly Biosciences | ASMB | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | Milestone Pharmaceuticals | MIST | Maintain | Hold (N/A) |
|
Details | ||
| 9/3/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 8/18/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 7/22/2025 | Indivior | INDV | New Coverage | Buy (N/A) |
16.01 (32.27) |
101.56% | Details | |
| 7/14/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 6/11/2025 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Hold (N/A) |
16.19 (26.59) |
64.24% | Details | |
| 6/5/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Lyra Therapeutics | LYRA | Maintain | Hold (N/A) |
|
Details | ||
| 3/3/2025 | Immunovant | IMVT | New Coverage | Hold (N/A) |
20.25 (26.66) |
31.65% | Details | |
| 1/21/2025 | Crinetics | CRNX | Upgrade | Buy (Hold) |
37.35 (38.23) |
2.36% | Details | |
| 12/31/2024 | Rhythm Pharmaceuticals | RYTM | New Coverage | Buy (N/A) |
56.34 (93.52) |
65.99% | Details | |
| 11/20/2024 | Ardelyx, Inc | ARDX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2024 | Inhibikase Therapeutics Inc | IKT | New Coverage | Buy (N/A) |
2.69 (1.88) |
-30.11% | Details | |
| 9/20/2024 | Assembly Biosciences | ASMB | Upgrade | Buy (Hold) |
18.17 (28.27) |
55.59% | Details | |
| 9/6/2024 | Amicus Therapeutics | FOLD | New Coverage | Buy (N/A) |
11.52 (14.31) |
24.22% | Details | |
| 9/3/2024 | Recursion Pharmaceuticals | RXRX | Maintain | Hold (N/A) |
|
Details | ||
| 7/17/2024 | Veru, Inc. | VERU | Maintain | Hold (N/A) |
|
Details | ||
| 7/9/2024 | Recursion Pharmaceuticals | RXRX | New Coverage | Hold (N/A) |
7.40 (3.46) |
-53.24% | Details | |
| 5/7/2024 | Lyra Therapeutics | LYRA | Downgrade | Hold (Buy) |
4.03 (1.28) |
-68.24% | Details | |
| 9/27/2023 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2023 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2023 | Milestone Pharmaceuticals | MIST | Downgrade | Hold (Buy) |
3.74 (1.58) |
-57.75% | Details | |
| 6/7/2023 | Veru, Inc. | VERU | Upgrade | Hold (Underperform) |
1.06 (2.47) |
133.02% | Details | |
| 5/30/2023 | Cara Therapeutics | CARA | New Coverage | Buy (N/A) |
3.28 (5.32) |
62.2% | Details | |
| 5/30/2023 | Lyra Therapeutics | LYRA | New Coverage | Buy (N/A) |
2.43 (1.28) |
-47.33% | Details | |
| 5/30/2023 | Ardelyx, Inc | ARDX | New Coverage | Buy (N/A) |
3.29 (6.19) |
88.15% | Details | |
| 4/3/2023 | Pardes Biosciences | PRDS | Downgrade | Hold (N/A) |
1.32 (2.16) |
63.64% | Details | |
| 2/24/2023 | Esperion Therapeutics | ESPR | New Coverage | Buy (N/A) |
5.83 (2.73) |
-53.17% | Details | |
| 2/15/2023 | Corcept Therapeutics | CORT | Downgrade | Hold (Buy) |
23.06 (33.87) |
46.88% | Details | |
| 12/19/2022 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Buy (Buy) |
12.00 (29.86) |
148.83% | Details | |
| 10/17/2022 | NGM Biopharmaceuticals | NGM | Downgrade | Hold (Buy) |
11.55 (1.54) |
-86.67% | Details | |
| 8/8/2022 | Cincor Pharma Inc | CINC | Maintain | Buy (N/A) |
|
Details | ||
| 7/27/2022 | Corcept Therapeutics | CORT | New Coverage | Buy (N/A) |
26.81 (33.87) |
26.33% | Details | |
| 7/20/2022 | NGM Biopharmaceuticals | NGM | New Coverage | Buy (N/A) |
15.01 (1.54) |
-89.74% | Details | |
| 2/2/2022 | Arbutus Biopharma | ABUS | Upgrade | Buy (Hold) |
2.81 (4.53) |
61.21% | Details | |
| 2/1/2022 | Cincor Pharma Inc | CINC | New Coverage | Buy (N/A) |
18.11 (29.06) |
60.46% | Details | |
| 1/18/2022 | Pardes Biosciences | PRDS | New Coverage | Buy (N/A) |
13.95 (2.16) |
-84.52% | Details | |
| 12/29/2021 | Arbutus Biopharma | ABUS | New Coverage | Hold (N/A) |
3.86 (4.53) |
17.36% | Details | |
| 11/30/2021 | Sigilon Therapeutics | SGTX | Downgrade | Hold (Buy) |
3.77 (22.47) |
496.02% | Details | |
| 10/26/2021 | Roivant Sciences | ROIV | New Coverage | Buy (N/A) |
7.04 (28.78) |
308.81% | Details |
